Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples